An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Homologous Recombination Deficiency score
研究概览
简要总结
This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue samples of patients with ovarian cancer using PARPi, and to determine the cut off value of the HRD score algorithm suitable for the Chinese population, so as to provide evidence for the role of PARPi in ovarian cancer. The screening of the beneficiaries of maintenance therapy provides precise guidance and can be used as a reference for other cancer types.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •age ≥ 18 years;
- •high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer;
- •FIGO stage III or IV;
- •at least 6 cycles and no more than 9 cycles First-line platinum-containing chemotherapy;
- •CR or PR after chemotherapy;
- •sufficient biological samples for HRD score detection;
- •patients signed informed consent;
- •good bone marrow function.
排除标准
- •incomplete follow-up records of survival information;
- •unqualified biological sample quality control
结局指标
主要结局
Homologous Recombination Deficiency score
时间窗: After the ovarian tissue is obtained, an average of 3 year
Optimize the Homologous Recombination Deficiency scoring algorithm to calculate the Homologous Recombination Deficiency score of each patient's ovarian cancer tissue
次要结局
未报告次要终点
研究者
Xin Wu
Department Director
Obstetrics & Gynecology Hospital of Fudan University